Increased syndecan-1 in serum is related to early nephropathy in type 1 diabetes mellitus patients.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed, 43 citations in OpenAlex.

1. Acute exercise increases syndecan-1 and -4 serum concentrations.Glycoconjugate journal · 2019
   Trial
2. Changes in Expression of Syndecans and Heparan Sulfate Biosynthesis Enzymes in Short-Term Streptozotocin-Induced Diabetic Rat Kidneys.Cells · 2026
   Article
3. The glomerular endothelial glycocalyx as a therapeutic target in proteinuric kidney disease.Nature reviews. Nephrology · 2026
   Review
4. Association of Visceral Fat Accumulation with Endothelial Glycocalyx Degradation in People with and without Type 2 Diabetes: A Retrospective Cross-sectional Study.Journal of atherosclerosis and thrombosis · 2025
   Article
5. Integrative biology of extracellular vesicles in diabetes mellitus and diabetic complications.Theranostics · 2022
   Review
6. Endothelial Glycocalyx Degradation in Critical Illness and Injury.Frontiers in medicine · 2022
   Review
7. Diabetes Mellitus-A Risk Factor for Unfavourable Outcome in COVID-19 Patients-The Experience of an Infectious Diseases Regional Hospital.Healthcare (Basel, Switzerland) · 2021
   Article
8. Blocking matrix metalloproteinase-mediated syndecan-4 shedding restores the endothelial glycocalyx and glomerular filtration barrier function in early diabetic kidney disease.Kidney international · 2020
   Article
9. Elevated Serum and Cerebrospinal Fluid CD138 in Patients With Anti-Frontiers in molecular neuroscience · 2019
   Article
10. Soluble syndecans: biomarkers for diseases and therapeutic options.British journal of pharmacology · 2019
    Review
11. Endothelial Glycocalyx as a Shield Against Diabetic Vascular Complications: Involvement of Hyaluronan and Hyaluronidases.Arteriosclerosis, thrombosis, and vascular biology · 2018
    Review
12. Effects of restoring normoglycemia in type 1 diabetes on inflammatory profile and renal extracellular matrix structure after simultaneous pancreas and kidney transplantation.Diabetes research and clinical practice · 2015
    Article
13. Association of kidney function with changes in the endothelial surface layer.Clinical journal of the American Society of Nephrology : CJASN · 2014
    Article
14. Diabetic nephropathy and extracellular matrix.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2012
    Review
15. Matrix metalloproteinases in subjects with type 1 diabetes.BMC clinical pathology · 2009
    Article
16. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers.Vascular health and risk management · 2008
    Review
17. Association of serum syndecan-1 concentrations with albuminuria in type 2 diabetes.Diabetes & vascular disease research
    Article

Corrections and comments

• Erratum issued
  Dosage error in article text

Authors and funding

3 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as